- Home
- DSP vs ATAI Comparison
DSP vs ATAI Comparison
Compare DSP & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- ATAI
- Stock Information
- Founded
- DSP 1999
- ATAI 2018
- Country
- DSP United States
- ATAI Germany
- Employees
- DSP N/A
- ATAI N/A
- Industry
- DSP EDP Services
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- ATAI Health Care
- Exchange
- DSP Nasdaq
- ATAI Nasdaq
- Market Cap
- DSP 291.3M
- ATAI 280.2M
- IPO Year
- DSP 2021
- ATAI 2021
- Fundamental
- Price
- DSP $12.24
- ATAI $1.48
- Analyst Decision
- DSP Strong Buy
- ATAI Strong Buy
- Analyst Count
- DSP 7
- ATAI 4
- Target Price
- DSP $23.29
- ATAI $9.00
- AVG Volume (30 Days)
- DSP 658.1K
- ATAI 2.9M
- Earning Date
- DSP 03-03-2025
- ATAI 03-27-2025
- Dividend Yield
- DSP N/A
- ATAI N/A
- EPS Growth
- DSP N/A
- ATAI N/A
- EPS
- DSP 0.14
- ATAI N/A
- Revenue
- DSP $289,235,000.00
- ATAI $331,000.00
- Revenue This Year
- DSP $13.31
- ATAI $80.07
- Revenue Next Year
- DSP $16.25
- ATAI N/A
- P/E Ratio
- DSP $86.47
- ATAI N/A
- Revenue Growth
- DSP 29.74
- ATAI N/A
- 52 Week Low
- DSP $7.77
- ATAI $0.78
- 52 Week High
- DSP $26.33
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- DSP 24.79
- ATAI 41.75
- Support Level
- DSP $12.76
- ATAI $1.37
- Resistance Level
- DSP $13.77
- ATAI $1.50
- Average True Range (ATR)
- DSP 1.28
- ATAI 0.14
- MACD
- DSP -0.71
- ATAI -0.04
- Stochastic Oscillator
- DSP 4.39
- ATAI 29.73
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.